Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Century Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Investor presentation
Docs: "Corporate Overview Aug 2023"
08/09/2023 8-K Investor presentation, Quarterly results
Docs: "Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates",
"Investor Presentation of Century Therapeutics, Inc."
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/29/2023 4 Carlo Rizzuto (Director) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 44,000 options to buy @ $3.19, valued at $140.4k
06/29/2023 4 Riva Alessandro (Director) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 44,000 options to buy @ $3.19, valued at $140.4k
06/29/2023 4 JIMENEZ JOSEPH (Director) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 44,000 options to buy @ $3.19, valued at $140.4k
06/29/2023 4 BUTITTA CYNTHIA M (Director) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 44,000 options to buy @ $3.19, valued at $140.4k
06/29/2023 4 Blackwell Kimberly (Director) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 44,000 options to buy @ $3.19, valued at $140.4k
06/29/2023 4 Quimi Daphne (Director) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 44,000 options to buy @ $3.19, valued at $140.4k
06/29/2023 4 Walbert Timothy P (Director) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 44,000 options to buy @ $3.19, valued at $140.4k
06/29/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/17/2023 4 Carr Douglas (SVP Finance & Operations) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 120,846 shares @ $0
05/17/2023 4 Diem Michael Craig (CFO) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 151,058 shares @ $0
05/11/2023 8-K Quarterly results
Docs: "Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K/A Quarterly results
05/05/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
04/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/14/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/13/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/05/2023 4 Borges Luis (Chief Scientific Officer) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Exercised 7,452 options to buy @ $1.03, valued at $7.7k
03/23/2023 4 Borges Luis (Chief Scientific Officer) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Sold 63,616 shares @ $3.7706, valued at $239.9k
Sold 65,698 shares @ $3.7237, valued at $244.6k
Sold 15,597 shares @ $3.55, valued at $55.4k
Exercised 63,616 options to buy @ $1.03, valued at $65.5k
Exercised 65,698 options to buy @ $1.03, valued at $67.7k
Exercised 220,930 options to buy @ $1.03, valued at $227.6k
03/23/2023 144 Form 144 - Report of proposed sale of securities:
03/22/2023 144 Form 144 - Report of proposed sale of securities:
03/21/2023 144 Form 144 - Report of proposed sale of securities:
03/20/2023 8-K Quarterly results
03/17/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 8-K Quarterly results
Docs: "Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates"
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/09/2023 SC 13G/A Versant Venture Capital VI, L.P. reports a 19.4% stake in Century Therapeutics, Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023 4 Flores Osvaldo (CEO) has filed a Form 4 on Century Therapeutics, Inc.
Txns: Granted 637,500 options to buy @ $4.64, valued at $3M
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy